| Sepsis induces long-term metabolic and mitochondrial muscle stem cell dysfunction amenable by mesenchymal stem cell therapy P Rocheteau, L Chatre, D Briand, M Mebarki, G Jouvion, J Bardon, ... Nature communications 6 (1), 10145, 2015 | 204 | 2015 |
| Human umbilical cord-derived mesenchymal stem/stromal cells: a promising candidate for the development of advanced therapy medicinal products M Mebarki, C Abadie, J Larghero, A Cras Stem Cell Research & Therapy 12, 1-10, 2021 | 96 | 2021 |
| Enhanced human bone marrow mesenchymal stromal cell adhesion on scaffolds promotes cell survival and bone formation M Mebarki, L Coquelin, P Layrolle, S Battaglia, M Tossou, P Hernigou, ... Acta Biomaterialia 59, 94-107, 2017 | 81 | 2017 |
| Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trial A Monsel, C Hauw-Berlemont, M Mebarki, N Heming, J Mayaux, ... Critical Care 26 (1), 48, 2022 | 73 | 2022 |
| Inferior in vivo osteogenesis and superior angiogeneis of human adipose-derived stem cells compared with bone marrow-derived stem cells cultured in xeno-free conditions MA Brennan, A Renaud, F Guilloton, M Mebarki, V Trichet, L Sensebé, ... Stem Cells Translational Medicine 6 (12), 2160-2172, 2017 | 58 | 2017 |
| Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients … R Liévin, R Di Blasi, F Morin, E Galli, V Allain, R De Jorna, L Vercellino, ... Bone Marrow Transplantation 57 (3), 431-439, 2022 | 38 | 2022 |
| Human-cell-derived organoids as a new ex vivo model for drug assays in oncology M Mebarki, A Bennaceur, L Bonhomme-Faivre Drug Discovery Today 23 (4), 857-863, 2018 | 33 | 2018 |
| Inferior in vivo osteogenesis and superior angiogenesis of human adipose‐derived stem cells compared with bone marrow‐derived stem cells cultured in Xeno‐free conditions. MA Brennan, A Renaud, F Guilloton, M Mebarki, V Trichet, L Sensebé, ... Stem Cells Translational Medicine 6 (12), 2160-2172, 2017 | 25 | 2017 |
| Development of a human umbilical cord-derived mesenchymal stromal cell-based advanced therapy medicinal product to treat immune and/or inflammatory diseases M Mebarki, N Iglicki, C Marigny, C Abadie, C Nicolet, G Churlaud, ... Stem Cell Research & Therapy 12, 1-15, 2021 | 22 | 2021 |
| Mesenchymal stem/stromal cell quality control: validation of mixed lymphocyte reaction assay using flow cytometry according to ICH Q2 (R1) T Nicotra, A Desnos, J Halimi, H Antonot, L Reppel, T Belmas, A Freton, ... Stem Cell Research & Therapy 11, 1-10, 2020 | 21 | 2020 |
| Real-world characteristics of T-cell apheresis and clinical response to tisagenlecleucel in B-cell lymphoma A Cuffel, V Allain, L Faivre, R Di Blasi, F Morin, L Vercellino, MF Chevalier, ... Blood Advances 6 (15), 4657-4660, 2022 | 12 | 2022 |
| In utero treatment of myelomeningocele with allogenic umbilical cord-derived mesenchymal stromal cells in an ovine model L Guilbaud, A Dugas, M Weber, C Deflers, P Lallemant, T Lilin, C Adam, ... Current Research in Translational Medicine 70 (1), 103314, 2022 | 11 | 2022 |
| Sepsis induces long-term metabolic and mitochondrial muscle stem cell dysfunction amenable by mesenchymal stem cell therapy. Nat Commun. 2015; 6: 10145 P Rocheteau, L Chatre, D Briand, M Mebarki, G Jouvion, J Bardon, ... Med Sci Sports Exer c 32, 2109-15, 2000 | 11 | 2000 |
| Positron emission tomography-imaging assessment for guiding strategy in patients with relapsed/refractory large B-cell lymphoma receiving CAR T cells J Galtier, L Vercellino, L Chartier, P Olivier, C Tabouret-Viaud, ... Haematologica 108 (1), 171, 2023 | 9 | 2023 |
| Early predictive factors of failure in autologous CAR T-cells manufacturing and/or efficacy in hematologic malignancies C Baguet, J Larghero, M Mebarki Blood Advances, 2023 | 6 | 2023 |
| Sepsis induces long-term metabolic and mitochondrial muscle stem cell dysfunction amenable by mesenchymal stem cell therapy. Nat Commun 6: 10145 P Rocheteau, L Chatre, D Briand, M Mebarki, G Jouvion, J Bardon, ... | 6 | 2015 |
| Inferior in vivo osteogenesis and superior angiogenesis of human adipose‐derived stem cells compared with bone marrow‐derived stem cells cultured in xeno‐free conditions MA Brennan, A Renaud, F Guilloton, M Mebarki, V Trichet, L Sensebé, ... Stem Cells Translational Medicine 7 (3), 315, 2018 | 5 | 2018 |
| PET-imaging assessment for guiding strategy in patients with relapsed/refractory large B-cell lymphoma receiving CAR T-cells J Galtier, L Vercellino, L Chartier, P Olivier, C Tabouret-Viaud, ... Haematologica 108, 171-180, 2022 | 4 | 2022 |
| Quality risk management of the chimeric antigen receptor T cell pharmaceutical circuit in one of the first qualified European centers C Talarmin, S Kerob, F Cartier, I Madelaine, S Mukenyi, E Schwartz, ... Cytotherapy 22 (12), 792-801, 2020 | 4 | 2020 |
| Advanced therapy medicinal products: regulatory framework, hospital and pharmaceutical circuits in Europe and France M Mebarki, I Madelaine, J Larghero, R de Jorna Therapies 77 (2), 185-190, 2022 | 2 | 2022 |
